Five Chinese companies face potential delisting from Wall Street if they fail to comply with new audit orders from the U.S. Securities and Exchange Commission (SEC). The SEC said that Yum China, BeiGene, Zai Lab, HutchMed and ACM are all at risk if…
Rules of engagement: navigating around traps when recruiting clinical trials via social media
Pharma has a chance at redefining its relationship to the public, allowing for direct interaction with potential clinical trial participants via social media. But what’s the risk? Need to Know: Social media can be a powerful tool to directly advertise…
A Win for AI: FDA Approves BioXCel Therapy for Bipolar Disorder and Schizophrenia
Connecticut-based BioXcel Therapeutics announced a win for artificial intelligence in the pharmaceutical industry. The U.S. Food and Drug Administration (FDA) has approved a sublingual film drug that aims to reduce the occurrence of agitation episodes in patients diagnosed with bipolar disorder…
Covid-19, flu combo vaccines an advance but with rollout quandaries
Experts were less keen on variant-specific or multivariant Covid-19 vaccines owing to lack of practical value despite scientific rationale. Need to know: In places where Covid-19 vaccines are easily accessible, many people who want to be vaccinated have already received…
